Population pharmacokinetic model for once-daily intravenous busulfan in pediatric subjects describing time-associated clearance

Rachael Lawson1,2 | Christine E. Staatz1 | Christopher J. Fraser3 | Shanti Ramachandran4 | Lochie Teague5 | Richard Mitchell6,7 | Tracey O’Brien6,7 | Stefanie Hennig8,9

1School of Pharmacy, University of Queensland, Brisbane, Queensland, Australia
2Pharmacy Department, Queensland Children's Hospital, Brisbane, Queensland, Australia
3Blood and Marrow Transplant Service, Queensland Children's Hospital, Brisbane, Queensland, Australia
4Oncology Department, Perth Children’s Hospital, Perth, Western Australia, Australia
5Pediatric Blood and Cancer Centre, Starship Hospital, Auckland, New Zealand
6Kids Cancer Centre, Sydney Children’s Hospital, Randwick, New South Wales, Australia
7School of Women & Children’s Health, University of New South Wales, Sydney, New South Wales, Australia
8Certara, Inc., Princeton, New Jersey, USA
9School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Australia

Abstract
This study aimed to characterize the population pharmacokinetics (PK) of busulfan focusing on how busulfan clearance (CL) changes over time during once-daily administration and assess different methods for measuring busulfan exposure and the ability to achieve target cumulative exposure under different dosing adjustment scenarios in pediatric stem cell transplantation recipients. Daily serial blood sampling was performed and concentration-time data were analyzed using a nonlinear mixed-effects approach. The developed PK model was used to assess achievement of target exposure under six dose-adjustment scenarios based on simulations performed in RStudio (RxODE package)*. A total of 2491 busulfan plasma concentration–time measurements were collected from 95 patients characterizing 379 dosing days. A two-compartment model with time-associated CL best described the data with a typical CL of 14.5 L/h for an adult male with 62 kg normal fat mass (NFM; equivalent to 70 kg total body weight), typical volume of distribution central compartment (V1) of 40.6 L/59 kg NFM (equivalent to 70 kg total body weight).

FUNDING A Study, Education and Research Trust Account Funding Scheme grant provided funds to perform busulfan analysis on some patient samples. An Australia and New Zealand Children’s Hematology/Oncology Group grant provided funds for transport of samples to the central laboratory.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Introduction

Busulfan is a bifunctional, alkylating agent commonly used in hematopoietic stem cell transplant (HSCT) conditioning regimens. Several studies have reported that intravenous (i.v.) busulfan clearance (CL) decreases during the course of treatment,1-7 with a reduction in CL ranging from 8.1% to 20%. It has been hypothesized that this may be due to busulfan metabolites competing with free busulfan for binding to glutathione-s-transferase (GST) enzymes and glutathione, resulting in reduced metabolism and glutathione depletion.8-11 One publication explored a semimechanistic model based on glutathione depletion to predict reduction in CL of busulfan. Investigators observed that the effect of glutathione depletion on CL of busulfan was proportional and increased in patients aged >40 years.11

Toxicity with busulfan therapy is well described, with monitoring to optimize busulfan exposure and improve treatment outcomes considered standard practice.10,12 The
American Society for Blood and Marrow Transplantation practice guidelines committee attempted to develop an evidence-based review about personalizing busulfan-based conditioning. However, published literature was too heterogeneous and lacked adequately powered controlled studies to provide a complete review, with guidance on only some aspects of personalizing busulfan dosing in children. Exposure monitoring should be performed due to an association between busulfan exposure and clinical outcomes, and validated pharmacokinetics (PK) modeling tools should be used. PK-guided dosing of i.v. busulfan was shown to be superior to fixed dosing based on patient body surface area in adults with acute myeloid leukemia and myelodysplastic syndrome with reduced relapse (38% vs. 56%), transplant-related mortality (24% vs. 39%), and an overall hazard ratio of 0.64 (95% confidence interval, 0.35–0.94) observed.

Busulfan exposure is estimated using various indices across the literature and in clinical practice, including the area under the concentration-time curve (AUC) over the dosing interval, the AUC over a 24-h period (AUC_{24h}), and cumulative AUC following all doses (AUC_{cum}). AUC_{cum} is increasingly being used for both the reporting of outcomes and for individual dose targeting during exposure monitoring. Bartelink et al. recommends an AUC_{cum} between 78 and 101 mg · h/L for optimal survival. Of note, AUC_{cum} in this publication was estimated using a model-based approach rather than noncompartmental analysis (NCA). There is an expected bias toward underestimation with NCA compared with model-based methods.

Busulfan dose adjustment across the typical 4-day treatment course can vary across treatment centers. Many centers adjust dosing based on the assumption that busulfan CL remains constant over time using product information recommendations despite contrary evidence of reduction in CL during the treatment course. Busulfan concentration measurement is commonly performed after the first dose only, with subsequent dosage adjustment made on Days 2 or 3. Application of a population model describing changes in CL of busulfan over time in a Bayesian forecasting program could assist with making dosage adjustments.

A recent review of published non-linear mixed effects (NLME) models for i.v. busulfan in children identified 21 studies; however, few focused on once-daily therapy or included samples from all 4 days of treatment to enable characterization of temporal changes in busulfan CL. Most common covariates shown to explain PK variability were patient total body weight (TBW), age, Glutathione-S-Transferase- A1 genotype, and busulfan dosing day/time since start of therapy.

This study aimed to (1) characterize the population PK of busulfan focusing on how busulfan CL changes over a typical 4-day treatment course by using a unique data set where sampling was performed following each administered dose and (2) assess different methods for estimating busulfan exposure and their ability to achieve target cumulative exposure under different dosing adjustment scenarios in pediatric subjects receiving once-daily i.v. busulfan for HSCT.

**METHODS**

**Subjects and data collection**

Data were collected both prospectively and retrospectively across three hospitals in Australia and one in New Zealand from 2016 to 2021. Ethics approval for the study was obtained from the human research ethics committees from all centers involved (HREC/16/QRCH/388, HREC:2017000073/HREC/16/RCH/388, HREC:RGS0000000497, HREC:18/CEN/10). Subjects were eligible for enrollment if they were HSCT recipients aged <18 years receiving once-daily i.v. busulfan and had adequate central venous access for blood sampling. All subjects received an initial once-daily i.v. infusion of busulfan between 3.2 and 4.8 mg/kg over 3 h, with dose calculated based on patient total weight as per Australian Busulfex® product information except for two obese patients where an adjusted dosing weight (adjusted body weight 25) was used. Subsequent doses across 4 days of treatment were modified to target an AUC_{cum} that was individualized for each patient based on clinical and disease factors. Blood samples for busulfan plasma concentration measurement were collected following each dose, from an alternative lumen to that used for administration, at 0 h (predose), 3 h (immediately following first flush), and 3.25, 4, 5, 6, and 8 h after the start of the infusion. Concentrations equal to or below the lower limit of quantification (LLOQ) were removed from the final data set used to build the NLME model. Demographic data including date of birth, age, sex, body surface area, weight, height and clinical data including diagnosis, liver function tests, measured glomerular filtration rate, serum albumin, prior chemotherapy, HSCT conditioning regimen, immunotherapy, supportive care medications, and coadministration of interacting medications including azole antifungal agents, metronidazole, acetaminophen, and seizure prophylaxis were collected. Busulfan doses administered, timing of administration, duration of infusion (DI), and individual subjects’ AUC_{cum} targets were all determined by the treating physician.

**Busulfan drug assay**

Samples collected from July 2014 onward for busulfan concentration measurement were analyzed at Pathology
Queensland using a validated reverse phase ultra-high performance liquid chromatography method with tandem mass spectrometry detection (UPLC-MS/MS). Following separation of plasma via centrifugation, the plasma samples were precipitated with methanol containing deuterated busulfan. Samples were then centrifuged, and supernatant was transferred to an autosampler vial and injected onto the UPLC-MS/MS system. Busulfan and internal standard were separated chromatographically using a C18 reverse phase column. Multiple reaction monitoring was then carried out for each individual analyte. The gradient was then returned to initial conditions in preparation for the next sample. Intra- and inter-run imprecision was less than 6%. Since July 2014, the assay has been shown to be linear from 0.01 to 20 mg/L with an LLOQ of 0.01 mg/L. For samples analyzed before July 2014, a similar assay was used with an LLOQ of 0.1 mg/L using precolumn derivatization with reverse-phase high-performance liquid chromatography. Subjects from Queensland had their samples tested immediately, whereas subjects from interstate or overseas centers had their separated plasma immediately frozen and stored and then transported on dry ice to the measurement laboratory no later than 6 months from freezing. Interstate and overseas subjects had separate samples tested in real time at their local laboratory to guide dose adjustments.

Model development and evaluation

NLME modeling PK analysis was performed using NONMEM* (Version 7.4.3, ICON) in conjunction with Perl Speaks NONMEM (Version 5.0) and Pirana (Version 2.9.9). R Studio* (Version 4.0.5; http://www.r-project.org) and Xpose* (http://xpose.sourceforge.net) were used for data exploration and visualization. Initially, one-, two-, and three-compartment models were trialed, with goodness-of-fit (GOF) diagnostic plots, evaluation of population fixed- and random-effects parameters, prediction-corrected visual predictive checks (pcVPC), and changes to the objective function value (OFV) used for model selection. Medians of the bootstrap estimate distributions and 95% confidence intervals from a nonparametric bootstrap analysis (N = 1000) were compared with final model estimates. Model parameters were estimated using first-order conditional estimation with interaction with predictions for population pharmacokinetics library models. A convergence criterion of three significant digits was used to identify successful minimization.

Information on duration of busulfan infusion (DI) was initially applied as recorded in patient medical records and was later included as a parameter to estimate. Interindividual variability (IIV) was explored on all parameters using an exponential model assuming a log-normal distribution. Additive, proportional, and combined additive and proportional residual error models were investigated.

Changes in busulfan CL over the course of treatment were explored during structural model building by including a covariate effect to examine the change in CL on each day in comparison to Day 1. A Michaelis–Menten concentration-dependent model and an empirical continuous time-associated model to describe the change in CL across dosing days were also tested. In the latter, the decrease in CL was described as shown in Equation (1):

$$\text{CL}_{i,t} = \text{CL}_{TV} \cdot \exp \left( \frac{\Delta \text{CL}_{max,i} \cdot t_i}{T_{50,i} + t_i} \right), \quad (1)$$

where CL_{i,t} is CL in the ith individual at a particular time t, \( \Delta \text{CL}_{max,i} \) is the maximal possible change in CL in the ith individual, t_i is time after the start of the infusion of the first dose in the ith individual in h, T_{50,i} is the time at which 50\% of \( \Delta \text{CL}_{max,i} \) is attained in h in the ith individual, and \( T_{50,i} \) describes the slope of the relationship. IIV on both \( \Delta \text{CL}_{max,i} \) and T_{50,i} were investigated using an exponential model assuming a log-normal distribution and removed if not supported.

The influence of body size and composition on PK parameters (SIZE_{param}) were incorporated following theory-based allometry as shown in Equation (2):

$$\text{SIZE}_{param,i} = \left( \frac{\text{Size}_i}{\text{Size}_{std}} \right)^{\gamma}, \quad (2)$$

where SIZE_{param,i} is the fractional difference in allometrically scaled size compared with an adult with TBW of 70 kg, Size_i is the individual patient size in kilograms, and Size_{std} was the standard weight in kg corresponding to a TBW of 70 kg in an adult. Size was expressed in terms of either TBW or normal fat mass (NFM) for the ith individual. Size_{std} was set at either an NFM of 62 kg for CL, 59 kg for typical volume of distribution central compartment (V1) and typical volume of distribution peripheral compartment (V2), and 56.1 kg for intercompartmental clearance (Q), corresponding to an allometrically scaled TBW of 70 kg or set to 70 kg if TBW was the size descriptor. Size descriptors including TBW and NFM are commonly used in published population PK models for busulfan in pediatrics. NFM has recently been used to identify differences between oncology versus non-oncology cohorts. In keeping with prior published pediatric models, the allometric exponent (power) in Equation (2) was fixed a priori to 0.75 for CL and Q and 1 for V1 and V2.

A maturation component was included on CL a priori. This was tested using Equation (3):

$$\text{SIZE}_{param,i} = \left( \frac{\text{Size}_i}{\text{Size}_{std}} \right)^{\gamma,}, \quad (3)$$
TABLE 1  Description of six scenarios and their underlying assumptions applied in the simulations

| Scenario name | Dose/s with concentration sampling | Dose/s at which change could occur | Method for calculation of AUC$_{0-24}$ | Method to calculate dose change | Method for calculating the change in dosage | Description and assumptions made |
|---------------|-----------------------------------|-----------------------------------|----------------------------------------|-----------------------------------|------------------------------------------|----------------------------------|
| NCA_PI_D1     | 1                                 | 2                                 | NCA                                    | Product Information-proportional  | Next dose calculated per product information equation based on NCA calculated AUC$_{0-24}$ after Dose 1, administered Dose 1 dosage (Current dose), and the next dose target AUC$_{0-24}$:
\[
\text{Next dose target AUC}_{0-24} (\text{mg} \cdot \text{h} / \text{L}) = \frac{90 \text{ mg} / \text{h} / \text{L} - \text{AUC}_{0-24}^\text{cumulative} (\text{mg} \cdot \text{h} / \text{L})}{\text{Number of doses remaining}},
\]
\[
\text{Next dose (mg)} = \frac{\text{Current dose (mg)} \cdot \text{Next dose target AUC}_{0-24} (\text{mg} / \text{h} / \text{L})}{\text{Actual AUC}_{0-24} (\text{mg} / \text{h} / \text{L})},
\]
where the number of doses remaining is 3 | NCA used to calculate AUC$_{0-24}$ for first dose only from samples taken at 0, 1, 2, and 4h from completion of infusion
Dose adjustment calculated using assumption that CL remains the same over the 4-day course (proportional adjustment as per product information) |
| NCA_PI_D1-4   | 1, 2, 3, 4                         | 2, 3, 4                           | NCA                                    | Product Information-proportional  | Next dose calculated per product information equation based on NCA calculated AUC$_{0-24}$ after each nth dose, current dose administered, and the next dose target AUC$_{0-24}$:
\[
\text{Next dose target AUC}_{0-24} (\text{mg} \cdot \text{h} / \text{L}) = \frac{90 \text{ mg} / \text{h} / \text{L} - \text{AUC}_{0-24}^\text{cumulative} (\text{mg} \cdot \text{h} / \text{L})}{\text{Number of doses remaining}},
\]
\[
\text{Next dose (mg)} = \frac{\text{Current dose (mg)} \cdot \text{Next dose target AUC}_{0-24} (\text{mg} / \text{h} / \text{L})}{\text{Actual AUC}_{0-24} (\text{mg} / \text{h} / \text{L})},
\]
where the number of doses remaining is 4–n | Assumption that busulfan concentration results available in time for adjustment of next dose
NCA used to calculate AUC$_{0-24}$ for all doses from samples taken at 0, 1, 2, and 4h from completion of infusion
Dose adjustment calculated using assumption that CL remains the same over the 4-day course (proportional adjustment as per product information) |
| MOD_PI_D1     | 1                                 | 2                                 | Model                                   | Product Information-proportional  | Next dose calculated per product information equation using a model-based calculated AUC$_{0-24}$ after Dose 1, administered Dose 1 dosage (Current dose), and the next dose target AUC$_{0-24}$:
\[
\text{Next dose target AUC}_{0-24} (\text{mg} \cdot \text{h} / \text{L}) = \frac{90 \text{ mg} / \text{h} / \text{L} - \text{AUC}_{0-24}^\text{cumulative} (\text{mg} \cdot \text{h} / \text{L})}{\text{Number of doses remaining}},
\]
\[
\text{Next dose (mg)} = \frac{\text{Current dose (mg)} \cdot \text{Next dose target AUC}_{0-24} (\text{mg} / \text{h} / \text{L})}{\text{Actual AUC}_{0-24} (\text{mg} / \text{h} / \text{L})},
\]
where the number of doses remaining is 3 | Model incorporating time-associated CL used to calculate AUC$_{0-24}$ for first dose only from samples taken at 0, 1, 2, and 4h from completion of infusion
Dose adjustment calculated using assumption that CL remains the same over the 4-day course (proportional adjustment as per product information) |
| Scenario name | Dose/s with concentration sampling | Dose/s at which change could occur | Method for calculation of AUC_{0–24} | Method to calculate dose change | Method for calculating the change in dosage | Description and assumptions made |
|---------------|----------------------------------|-----------------------------------|--------------------------------------|---------------------------------|----------------------------------|-----------------------------------|
| MOD_P_L_D1-4  | 1, 2, 3, 4                       | 2, 3, 4                           | Model¹                              | Product information-proportional | Next dose calculated per product information equation using a model-based calculated AUC_{0–24} after each n th dose, current dose administered, and the next dose target AUC_{0–24}:

\[
\text{Next dose target AUC}_{0–24} \text{ (mg · h/L) } = \frac{(90 \text{ mg · h/L} – \text{AUC}_{\text{cum}} \text{ (all doses administered) (mg · h/L)})}{\text{Number of doses remaining}}
\]

Next dose (mg) = \text{Current dose (mg) · Next dose target AUC}_{0–24} \text{ (mg · h/L)}

where the number of doses remaining is: 4–n | Assumption that busulfan concentration results available in time for adjustment of next dose |
| MOD_P_L_D1    | 1                                | 2                                 | Model                              | Model-calculated CL_{i}         | Next dose calculated using model-based calculated AUC_{0–24} after administered Dose 1, the model-based calculated CL_{i} after Dose 1, and the next dose target AUC_{0–24}:

\[
\text{Next dose target AUC}_{0–24} \text{ (mg · h/L) } = \frac{(90 \text{ mg · h/L} – \text{AUC}_{\text{cum}} \text{ (all doses administered) (mg · h/L)})}{\text{Number of doses remaining}}
\]

Next dose (mg) = \text{CL}_{i} · \text{Dose}_{1} · \text{Next dose target AUC}_{0–24} | Model incorporating time-associated CL used to calculate AUC_{0–24} for all doses from samples taken at 0, 1, 2, and 4 h from completion of infusion |
| MOD_P_L_D1-4  | 1, 2, 3, 4                       | 2, 3, 4                           | Model                              | Model-calculated CL_{i}         | Next dose calculated using model based calculated AUC_{0–24} after each n th dose, the model-based calculated CL_{i} after each n th dose, and the next dose target AUC_{0–24}:

\[
\text{Next dose target AUC}_{0–24} \text{ (mg · h/L) } = \frac{(90 \text{ mg · h/L} – \text{AUC}_{\text{cum}} \text{ (all doses administered) (mg · h/L)})}{\text{Number of doses remaining}}
\]

Next dose (mg) = \text{CL}_{i} · \text{Dose}_{n} · \text{Next dose target AUC}_{0–24} | Assumption that busulfan concentration results available in time for adjustment of next dose |

Note: For all scenarios, initial dose was calculated according to product information based on simulated patient weight (five weight-based strata: <9 kg–4 mg/kg/dose, 9 to <16 kg–4.8 mg/kg/dose, 16–23 kg–4.4 mg/kg/dose, >23–34 kg–3.8 mg/kg/dose, >34 kg–3.2 mg/kg/dose), and all individuals had a target AUC_{cum} of 90 mg · h/L. Abbreviations: actual AUC_{0–24}, area under the concentration-time curve over a 24-h period calculated based on the current dose administered; AUC_{cum}, cumulative area under the concentration-time curve following all doses; AUC_{cum(all doses administered)}, cumulative area under the time versus concentration curve for all doses administered; CL, clearance; CL_{i}, individual model-based clearance calculated at the end of the dosing interval for the current dose; CL_{i,s}, individual model-based clearance calculated at the end of the dosing interval for the n th dose; Current dose, current dose administered; NCA, noncompartmental analysis; next dose target AUC_{0–24}, remaining exposure to the target AUC_{cum} divided by the number of doses remaining.

¹Model-based AUC_{0–24} and AUC_{cum} were calculated by numeric integration using Rstudio® RxOde package from 0 to 24 h post dose.
where $F_{\text{mat},i}$ describes the maturation process, PMA is postmenstrual age in weeks for the $i$th individual, and TM50 is the PMA in weeks where the CL of busulfan is considered to be 50% of the adult value, and the Hill coefficient represents the steepness of the function. Subjects in this study were assumed to have been born at term (i.e., 40 weeks PMA). The Hill coefficient was estimated and fixed to 2.3. TM50 was fixed to 45.6 weeks as supported by two studies involving 540 and 1610 patients, respectively. Lastly, intraoccasional variability (IOV) was modeled using an additional random-effects parameter and was tested one by one on CL, V1, Q, and V2.

Structural and stochastic models were selected based on GOF and a reduction in OFV by $\geq 3.84$ points for one degree of freedom at $p < 0.05$ between nested models by model performance, including convergence and precision of parameter estimates. Thereafter, additional covariates were tested on CL in a stepwise process based on physiological plausibility and literature review and model performance, including convergence and precision of parameter estimates. Thereafter, additional covariates were tested on CL in a stepwise process based on physiological plausibility and literature review and retained in the model if statistically significant based on a $\chi^2$ test ($p < 0.05$). Covariates tested included use of concurrent medications for seizure prophylaxis, antifungal agents, acetaminophen, and fludarabine and an oncology versus nononcology diagnosis. The influence of interacting medications was tested on both $\Delta CL_{\text{max},i}$ and time at which 50% of $\Delta CL_{\text{max},i}$ is attained ($T_{50,i}$) using Equation (1).

### Dose-adjustment simulations

Six different dose-adjustment scenarios were compared based on random simulation of a virtual population of 1000 subjects whose age, height, sex, and TBW were sampled from distributions with the same mean and standard deviation as the study population using RStudio (RxODE® package). Sex was randomized with a similar distribution as the study population. Dose 1 (D1) was calculated from TBW according to the product information. A summary of the different scenarios and their underlying assumptions is provided in Table 1. Dosing scenarios were designed to reflect common situations described in the literature and seen in clinical practice. Busulfan concentrations were simulated based on the model and sampling times at 0, 1, 2, and 4 h post infusion as currently recommended within the product information. These were then used to obtain daily exposure estimates (AUC0–24) either determined using the developed model by numeric integration (signified by NCA in the scenario name) or using NCA (signified by PI in the scenario name). Sampling from D1 only versus sampling following each of the four doses indicated as D1 or D1–4 in the scenario name was compared together with the method to calculate the next dose. Dosage adjustment was either based on a proportional relationship (as suggested in the product information) or using individual CL (CLi) estimates from the model immediately prior to the next dose (signified with MOD in the scenario name). In all scenarios, an AUCcum of 90 mg · h/L was targeted, the middle point of the optimal target range recommended by Bartelink and colleagues. The proportion of subjects who obtained exposure within 5% of the 90 mg · h/L target and the number and proportion of subjects who obtained exposure within the optimal target range of 78–101 mg · h were reported across the different scenarios. AUCcum reported for all scenarios was determined using the RxODE package in R using the final NLME model developed in this study. Using numeric integration AUCcum was determined from AUC0–24 for Doses 1–3 and then AUC0–∞ for Dose 4. The sample R code for key components of the simulation can be found in the Supplementary Material.

### RESULTS

**Subjects and data**

Data were collected from a total of 95 pediatric HSCT subjects (49 retrospectively, 46 prospectively) who had received i.v. busulfan administered once daily across 4 days. Samples below the LLOQ (5.3%) were all predose values and were not included in the data analysis. A total of 80 patients were from the Queensland Children’s Hospital in Brisbane (Center 1), whereas the remaining 15 came from three interstate or overseas centers (Perth Children’s Hospital, Sydney Children’s Hospital, or Auckland Starship Children’s Hospital). The final PK model was developed based on 2491 busulfan plasma concentration–time measurements from 379 dosing days. One patient had eight blood samples that were compromised and needed to be discarded, one patient had only 3 days of treatment, and another had an additional dose administered to total 5 days of therapy. The demographic and clinical characteristics of the subjects together with the busulfan exposure targets and estimated busulfan exposure attained using NCA are summarized in Table 2.

**PK model**

A two-compartment model with first-order elimination best described the concentration-time data (change in
| Description                                        | Nonmalignant (N = 15) | Malignant (N = 80) | Total (N = 95) |
|----------------------------------------------------|------------------------|-------------------|---------------|
| **Sex, n (%)**                                     |                        |                   |               |
| Male                                               | 13 (86.7)              | 36 (45.0)         | 49 (51.6)     |
| Female                                             | 2 (13.3)               | 44 (55.0)         | 46 (48.4)     |
| **Age, years**                                     |                        |                   |               |
| Median [lower 2.5%, upper 97.5%]                   | 2.80 [0.375, 7.49]     | 4.50 [1.40, 17.3] | 4.20 [0.735, 17.2] |
| **Actual weight, kg**                              |                        |                   |               |
| Median [lower 2.5%, upper 97.5%]                   | 13.8 [6.03, 26.3]      | 17.6 [10.0, 85.5] | 17.0 [7.77, 83.3] |
| **Body mass index, kg/m²**                         |                        |                   |               |
| Median [lower 2.5%, upper 97.5%]                   | 17.5 [13.8, 19.17]     | 18.4 [13.39, 30.64] | 18.2 [13.35, 32.39] |
| **Treatment center, n (%)**                        |                        |                   |               |
| Center 1                                           | 14 (93.3)              | 66 (82.5)         | 80 (84.2)     |
| Centers 2–4                                        | 1 (6.7)                | 14 (17.5)         | 15 (15.8)     |
| **Chemotherapy regimen, n (%)**                    |                        |                   |               |
| Bu/Flu                                             | 12 (80.0)              | 12 (15.0)         | 24 (25.3)     |
| Bu/Flu/Mel                                         | 0 (0)                  | 19 (23.8)         | 19 (20.0)     |
| Bu/Cy                                              | 0 (0)                  | 5 (6.2)           | 5 (5.3)       |
| Bu/Flu/TT                                          | 2 (13.3)               | 22 (27.5)         | 24 (25.3)     |
| Bu/Cy/TT                                           | 0 (0)                  | 0 (0)             | 0 (0)         |
| Bu/Mel                                             | 0 (0)                  | 21 (26.2)         | 21 (22.1)     |
| Other                                              | 1 (6.7)                | 1 (1.2)           | 2 (2.1)       |
| **Seizure prophylaxis, n (%)**                     |                        |                   |               |
| Levetiracetam                                      | 13 (86.7)              | 58 (72.5)         | 71 (74.7)     |
| Benzodiazepine                                     | 1 (6.7)                | 22 (27.5)         | 23 (24.2)     |
| Other                                              | 0 (0)                  | 0 (0)             | 0 (0)         |
| Missing                                            | 1 (6.7)                | 0 (0)             | 1 (1.1)       |
| **Immunotherapy, n (%)**                           |                        |                   |               |
| None                                               | 1 (6.7)                | 43 (53.8)         | 44 (46.3)     |
| ATGAM*                                             | 0 (0)                  | 5 (6.3)           | 5 (5.3)       |
| Thymoglobulin*                                     | 11 (73.3)              | 1 (1.3)           | 12 (12.6)     |
| Grafalon*                                          | 1 (6.7)                | 25 (31.3)         | 26 (27.4)     |
| Alemtuzumab                                        | 1 (6.7)                | 0 (0)             | 1 (1.1)       |
| Missing                                            | 1 (6.7)                | 6 (7.5)           | 7 (7.4)       |
| **Metronidazole, n (%)**                           |                        |                   |               |
| No                                                 | 14 (93.3)              | 66 (82.5)         | 80 (84.2)     |
| Yes                                                | 0 (0)                  | 3 (3.8)           | 3 (3.2)       |
| Missing                                            | 1 (6.7)                | 11 (13.8)         | 12 (12.6)     |
| **Acetaminophen, n (%)**                           |                        |                   |               |
| No                                                 | 3 (20.0)               | 35 (43.8)         | 38 (40.0)     |
| Yes                                                | 12 (80.0)              | 36 (45.0)         | 48 (50.5)     |
| Missing                                            | 0 (0)                  | 9 (11.2)          | 9 (9.5)       |
| **Posaconazole, n (%)**                            |                        |                   |               |
| No                                                 | 14 (93.3)              | 66 (82.5)         | 80 (84.2)     |
| Yes                                                | 0 (0)                  | 4 (5.0)           | 4 (4.2)       |
| Missing                                            | 1 (6.7)                | 10 (12.5)         | 11 (11.6)     |
(Continues)
A combined residual error was superior to a proportional error (ΔOFV −652 compared with a proportional error model). Estimating DI was superior to using the recorded duration listed in the medical notes (ΔOFV −43). DI was later fixed to 2.43 h and confirmed using a sensitivity analysis. Addition of time-associated CL based on a continuous model (Equation 1) improved the model fit further (ΔOFV −493.2). In terms of the stochastic model, inclusion of IIV on CL and V1 with correlation (ΔOFV −232.2), inclusion of IOV on CL (ΔOFV −1147), and inclusion of IOV on V1 (ΔOFV −156.3) all improved the model fit.

During covariate screening, inclusion of allometrically scaled NFM on CL, Q, V1, and V2 (Equation 2) together with a maturation function on CL (Equation 3) significantly improved the fit of the model (ΔOFV −232.2), inclusion of IOV on CL (ΔOFV −1147), and inclusion of IOV on V1 (ΔOFV −156.3) all improved the model fit.

A trend toward a difference in CL, T50,i and ΔCLmax,i with the use of an azole antifungal was observed but requires further investigation with additional subjects and hence was not included in the final model. There was no difference in CL observed in subjects with and without malignant disease.

Population PK parameter estimates for the final model are summarized in Table 3. Standard errors for the final model parameter estimates showed that parameters were well estimated and were below 25% for all except for T50,i which had a relative standard error (RSE) of 35%. The pcVPCs for the final model showed good agreement between the observed and predicted data across all days (Figure 1). Results from the nonparametric bootstrap analysis demonstrated that final model estimates were robust (Table 3). GOF plots are shown in Figure S1, demonstrating adequate model fit.

Simulations: six dosing scenarios for the virtual population

Table 4 shows the predicted AUCcum for the same virtual population of 1000 simulated subjects for each of the Scenarios 1–6. When an AUC0–24 was estimated following D1 only using NCA to determine the next doses (Doses 2–4) using the equation from the product information (NCA_PI_D1), a median AUCcum of 129 mg · h/L (range,
| Parameter                | Final model | Bootstrap analysis |
|--------------------------|-------------|--------------------|
|                         | Estimate    | RSE (%)            | Shrinkage (%) | Median  | 5th CI | 95th CI |
| CL (L/h/62 kg)          | 14.5        | 5.86               | –             | 14.7    | 13.1   | 16.9    |
| V1 (L/59 kg)            | 40.6        | 4.42               | –             | 40.5    | 37.3   | 43.7    |
| Q (L/h/56.1 kg)         | 1.92        | 22.9               | –             | 2.02    | 1.23   | 3.17    |
| V2 (L/59 kg)            | 3.57        | 15.9               | –             | 3.70    | 2.73   | 4.81    |
| DI (h)                  | 2.43 (fixed)| –                  | –             | 2.43    | –      | –       |
| ΔCLmax                  | −0.198      | 16.9               | –             | −0.193  | −0.283 | −0.146  |
| T50 (h)                 | 50.6        | 34.6               | –             | 49.6    | 24.1   | 106     |
| IIV on CL (CV%)         | 14.7%       | 12.4               | 1.96          | 14.3%   | 10.9%  | 17.6%   |
| IIV on V1 (CV%)         | 34.9%       | 20.1               | 0.997         | 34.5%   | 20.6%  | 46.0%   |
| IOV on CL (CV%)         | 6.61%       | 8.77               | 13.9          | 6.47%   | 5.35%  | 7.53%   |
| IOV on V1 (CV%)         | 9.71%       | 9.61               | 28.9          | 9.64%   | 8.11%  | 11.2%   |
| Prop RUV (CV%)          | 24.3%       | 5.12               | –             | 24.3%   | 23.2%  | 25.3%   |
| Add RUV (mg/L)          | 0.0300      | 22.9               | –             | 0.0297  | 0.0182 | 0.0405  |
| Ffat(CL)                | 0.509 (fixed)| –                  | –             | 0.509   | –      | –       |
| Ffat(V1)                | 0.203 (fixed)| –                  | –             | 0.203   | –      | –       |
| Ffat(Q)                 | 0 (fixed)   | –                  | –             | 0 (fixed)| –     | –       |
| Ffat(V2)                | 0.203 (fixed)| –                  | –             | 0.203   | –      | –       |
| Hill (maturation)       | 2.3 (fixed) | –                  | –             | 2.3 (fixed)| –    | –       |
| TM50 (maturation)       | 45.6 (fixed)| –                  | –             | 45.6 (fixed)| –    | –       |

Note: CL, Q, V1, and V2 parameter estimates were allometrically scaled using a standard NFM of 62 kg for CL, 56.1 kg for Q, and 59 kg for V1 and V2 corresponding to an allometrically scaled total body weight of 70 kg. Coefficient of Variation (CV%) are calculated as the Square root of variance (OMEGA from NONMEM®) × 100; RSE of parameter estimates are calculated as 100×(SE/typical value); RSE of between-subject variability magnitude are calculated as 100×(SE/variability estimate)/2. Proportional RUV is presented as standard deviation. Shrinkage (%) is calculated as 100×(1 − SD (ETA from NONMEM®)/sqrt(variance)). Overall residual variability shrinkage was estimated to be 14.5%. The correlation coefficient between CL and V1 was estimated as 0.0295. Hill = the steepness of the function within CLmat equation.

Abbreviations: ΔCLmax, maximal possible change in CL relative to baseline for the individual; Add RUV, additive residual unexplained variability; CL, confidence interval; CLmat, clearance maturation; DI, duration of infusion; Ffat(CL), the fraction of fat mass (Ffat) contributing to NFM for CL parameter; Ffat(V1), the fraction of fat mass (Ffat) contributing to NFM for V1 parameter; Ffat(Q), the fraction of fat mass (Ffat) contributing to NFM for Q parameter; Ffat (V2), the fraction of fat mass (Ffat) contributing to NFM for V2 parameter; IOV, intraoccasion variation; IIV, interindividual variation; NFM, normal fat mass; Prop RUV, proportional residual unexplained variability; Q, intercompartmental clearance; RSE, relative standard error; T50, time at which 50% of ΔCLmax is attained; TM50, Post menstrual age in weeks where the CL of busulfan is considered to be 50% of the adult value; V1, volume of distribution central compartment; V2, volume of distribution peripheral compartment.

**FINAL MODEL**

Central compartment

\[
\frac{dc}{dt} = Q \cdot CONC + Q \cdot PERI - CL \cdot EXP\left(-0.198 \cdot \frac{Time^1}{(50.6^1 + Time^1)}\right) \cdot CONC
\]

Peripheral compartment

\[
\frac{dc}{dt} = Q \cdot CONC - Q \cdot PERI
\]

Parameters

\[
CL = 14.5 \cdot CL_{SIZE} \cdot CL_{MAT}
\]

\[
V1 = 40.6 \cdot V_{SIZE}
\]

\[
Q = 1.92 \cdot Q_{SIZE}
\]

\[
V2 = 3.57 \cdot V_{SIZE}
\]

where \(\frac{dc}{dt}\) = change in concentration over time, CONC = concentration busulfan in central compartment (V1) in mg/L, PERI = concentration busulfan in peripheral compartment (V2) in mg/L, and Time¹ = time in h since beginning of infusion of Dose 1, \(CL_{size}\) = Equation 2 for CL, \(CL_{mat}\) = Equation 3.
105–241) (Table 4, Figure 2) was obtained and 100% of patients were above both the individualized target AUC\textsubscript{cum} of 90 mg · h/L ±5% and the target range of 78–101 mg · h/L (Table 4). When sampling was performed and considered following each dose (Scenario NCA\_PI\_D1-4) the median AUC\textsubscript{cum} of 125 mg · h/L (range, 100–231) remained high, and the proportion of subjects achieving target was considerably reduced compared with scenarios using model-based exposure estimates (MOD\_PI\_D1-4 and MOD\_MOD\_D1-4). Under Scenario NCA\_PI\_D1-4, all subjects had above target exposure (Table 4). When AUC\textsubscript{0–24} was estimated using model-based methods following D1 only to calculate the next doses (Doses 2–4) from the equation within the product information (MOD\_PI\_D1), median AUC\textsubscript{cum} achieved was lower compared with Scenario NCA\_PI\_D1 at 96.9 mg· h/L (range, 95.7–98.6) (Table 4, Figure 2), with 100% of patients achieving exposure within the optimal exposure target range (78–101 mg · h/L; Table 4, Figure 2) but 100% above target exposure of 90 mg · h/L ±5%. When sampling was performed following each dose (MOD\_PI\_D1-4), the median AUC\textsubscript{cum} achieved was 90.5 mg· h/L (range, 90.4–91.2), and all subjects achieved target exposure (100% within 90 mg· h/L ±5%) as seen in Figure 2. When model-based AUC\textsubscript{0–24} and individual CL\textsubscript{i} estimates (immediately prior to Dose 2) were used to calculate Doses 2–4 from sampling following D1 only (MOD\_MOD\_D1), the median AUC\textsubscript{cum} achieved was 92.4 mg· h/L (range, 91.9–92.9). When sampling was performed following D1 only, this scenario performed best with all patients attaining the target AUC\textsubscript{cum} of 90 mg · h /L ±5% (Table 4). When samples were taken with each dose allowing subsequent dose adjustments (MOD\_MOD\_D1-4), the median AUC\textsubscript{cum} was 90 mg· h/L (range, 90–90.8), with all subjects within the target range (Figure 2).

Scenarios using NCA to estimate exposure (NCA\_PI\_D1 and NCA\_PI\_D1-4) were associated with the highest mean and median doses administered, the highest estimated daily AUC\textsubscript{0–24} and AUC\textsubscript{cum}, and all patients were above target exposure. When model-based exposure estimates were used, all patients achieved busulfan exposure within the optimal target range of 78–101 mg · h/L. In these four scenarios, using the proportional method to calculate next dose for Doses 2–4 (MOD\_PI\_D1) with sampling performed following D1 only led to more subjects attaining >5% above target AUC\textsubscript{cum} compared with when model-based CL\textsubscript{i} estimates were used (MOD\_MOD\_D1 [100% vs. 0%; Table 4]). Higher doses were suggested when using the proportional dose equation compared with model-based CL\textsubscript{i} (Table 4), corresponding to higher AUC\textsubscript{0–24} exposure, particularly following Dose 2 (Table 4, Figure S2). Scenarios MOD\_PI\_D1-4, MOD\_MOD\_D1, and MOD\_MOD\_D1-4 were associated with smaller dose adjustments and reduced doses during the 4-day treatment course compared with Scenarios NCA\_PI\_D1, NCA\_PI\_D1-4, and MOD\_PI\_D1.

**DISCUSSION**

This is the largest study to date to characterize the PK of busulfan based on data from all 4 days of treatment in pediatric HSCT subjects. The final population PK model adequately predicted individual busulfan concentrations. Busulfan demonstrated a time-associated reduction in CL during the course of treatment. The average reduction in CL was 11.6%, with 8.1% reduction occurring within 48 h following initiation of therapy. This finding is in keeping with other studies that have reported reductions in CL of between 8.1% and 20%\textsuperscript{1–7} (Table S1). RSE on T\textsubscript{50} was 35%,
and bootstrap results had a large range. This parameter may have some predictable variation between patients that is yet to be described and could be related to concomitant azole administration. Azole antifungals each have different potential to induce and/or inhibit different cytochrome P450 enzyme subfamilies as well as compete for metabolism as a substrate, potentially impacting metabolism pathways for busulfan.

### Table 4

Results of simulation AUC\(_{\text{cum}}\) targets achieved and doses administered based on six different dose-adjustment scenarios (N = 1000 virtual simulated subjects)\(^a\)

|                        | NCA\_PI\_D1 (N = 1000) | NCA\_PI\_D1-4 (N = 1000) | MOD\_PI\_D1 (N = 1000) | MOD\_PI\_D1-4 (N = 1000) | MOD\_MOD\_D1 (N = 1000) | MOD\_MOD\_D1-4 (N = 1000) |
|------------------------|------------------------|--------------------------|------------------------|--------------------------|------------------------|--------------------------|
| **Subjects who achieved AUC(CUM) targets, n (%)** |                        |                          |                        |                          |                        |                          |
| AUC\(_{\text{cum}}\) achieve 90 mg \cdot h/L ±5% |                        |                          |                        |                          |                        |                          |
| Below                  | 0 (0)                  | 0 (0)                    | 0 (0)                  | 0 (0)                    | 0 (0)                  | 0 (0)                    |
| Within                 | 0 (0)                  | 0 (0)                    | 0 (0)                  | 1000 (100)               | 1000 (100)             | 1000 (100)               |
| Above                  | 1000 (100)             | 1000 (100)               | 1000 (100)             | 0 (0)                    | 0 (0)                  | 0 (0)                    |
| AUC\(_{\text{cum}}\) achieve within 78–101 mg \cdot h/L |                        |                          |                        |                          |                        |                          |
| Below                  | 0 (0)                  | 0 (0)                    | 0 (0)                  | 0 (100)                  | 0 (0)                  | 0 (0)                    |
| Within                 | 0 (0)                  | 2 (0.2)                  | 1000 (100)             | 1000 (100)               | 1000 (100)             | 1000 (100)               |
| Above                  | 1000 (100)             | 998 (99.8)               | 0 (0)                  | 0 (0)                    | 0 (0)                  | 0 (0)                    |
| **Dose administered each day (mg)** |                        |                          |                        |                          |                        |                          |
| Dose 1                 |                        |                          |                        |                          |                        |                          |
| Mean (SD)              | 98.5 (52.3)            | 98.5 (52.3)              | 98.5 (52.3)            | 98.5 (52.3)              | 98.5 (52.3)            | 98.5 (52.3)              |
| Median [min, max]      | 92.1 [21.2, 351]       | 92.1 [21.2, 351]         | 92.1 [21.2, 351]       | 92.1 [21.2, 351]         | 92.1 [21.2, 351]       | 92.1 [21.2, 351]         |
| Dose 2                 |                        |                          |                        |                          |                        |                          |
| Mean (SD)              | 232 (122)              | 232 (122)                | 162 (88.3)             | 162 (88.3)               | 153 (83.4)             | 153 (83.4)               |
| Median [min, max]      | 208 [50.4, 1280]       | 208 [50.4, 1280]         | 145 [35.7, 654]        | 145 [35.7, 654]          | 137 [33.7, 616]        | 137 [33.7, 616]          |
| Dose 3                 |                        |                          |                        |                          |                        |                          |
| Mean (SD)              | 232 (122)              | 87.0 (46.7)              | 162 (88.3)             | 148 (80.6)               | 153 (83.4)             | 148 (80.6)               |
| Median [min, max]      | 208 [50.4, 1280]       | 81.0 [18.5, 314]         | 145 [35.7, 654]        | 132 [32.6, 595]          | 137 [33.7, 616]        | 132 [32.6, 595]          |
| Dose 4                 |                        |                          |                        |                          |                        |                          |
| Mean (SD)              | 232 (122)              | 345 (191)                | 162 (88.3)             | 139 (75.5)               | 153 (83.4)             | 145 (78.8)               |
| Median [min, max]      | 208 [50.4, 1280]       | 309 [74.0, 2130]         | 145 [35.7, 654]        | 124 [30.5, 557]          | 137 [33.7, 616]        | 129 [31.9, 583]          |
| **AUC\(_{\text{cum}}\) following each dose (mg \cdot h/L)** |                        |                          |                        |                          |                        |                          |
| AUC\(_{\text{cum}}\) h24 (mg \cdot h/L) |                        |                          |                        |                          |                        |                          |
| Mean (SD)              | 15.4 (2.59)            | 15.4 (2.59)              | 15.4 (2.59)            | 15.4 (2.59)              | 15.4 (2.59)            | 15.4 (2.59)              |
| Median [min, max]      | 15.1 [9.05, 28.5]      | 15.1 [9.05, 28.5]        | 15.1 [9.05, 28.5]      | 15.1 [9.05, 28.5]        | 15.1 [9.05, 28.5]      | 15.1 [9.05, 28.5]        |
| AUC\(_{\text{cum}}\) h48 (mg \cdot h/L) |                        |                          |                        |                          |                        |                          |
| Mean (SD)              | 53.9 (6.51)            | 53.9 (6.51)              | 41.8 (1.68)            | 41.8 (1.68)              | 40.3 (1.73)            | 40.3 (1.73)              |
| Median [min, max]      | 52.6 [42.6, 88.5]      | 52.6 [42.6, 88.5]        | 41.6 [37.7, 50.3]      | 41.6 [37.7, 50.3]        | 40.1 [36.1, 49.1]      | 40.1 [36.1, 49.1]        |
| AUC\(_{\text{cum}}\) h72 (mg \cdot h/L) |                        |                          |                        |                          |                        |                          |
| Mean (SD)              | 93.8 (12.9)            | 68.8 (7.28)              | 69.1 (0.728)           | 66.7 (0.810)             | 66.1 (0.836)           | 65.2 (0.864)             |
| Median [min, max]      | 90.6 [73.6, 164]       | 67.8 [53.0, 107]         | 69.0 [67.3, 72.7]      | 66.6 [64.7, 70.8]        | 66.0 [64.0, 70.3]      | 65.1 [63.1, 69.6]        |
| AUC\(_{\text{cum}}\) h96 (mg \cdot h/L) |                        |                          |                        |                          |                        |                          |
| Mean (SD)              | 134 (19.6)             | 129 (18.6)               | 96.9 (0.271)           | 90.5 (0.0569)            | 92.4 (0.104)           | 90.1 (0.0633)            |
| Median [min, max]      | 129 [105, 241]         | 125 [100, 231]           | 96.9 [95.7, 98.6]      | 90.5 [90.4, 91.2]        | 92.4 [91.9, 92.9]      | 90.0 [90.0, 90.8]        |

Abbreviations: AUC\(_{\text{cum}}\), cumulative exposure of busulfan over the entire course (4 days); h, hour; L, liter; mg, milligram; max, maximum; min, minimum; SD, standard deviation.

\(^a\)Scenario descriptions are in Table 1.
An empirical Emax model was explored to describe time-associated busulfan CL as it allows for a reduction in CL over time without CL achieving zero or negative values, which are physiologically implausible. This model has been used previously for busulfan and described the data well. The biological rationale for the observed reduction in busulfan CL with continued therapy requires further exploration. It is possible that busulfan metabolites (tetrahydrothiophene and γ-glutamyldehydroalanylglycine) may interfere with busulfan biotransformation or alternatively glutathione depletion may play a role. NFM was the preferred size descriptor, which is in keeping with one of the largest published NLME models to date. The PK parameters in the final model were similar to previously published values as reported in a recent review. Typical population CL was estimated to be 14.5 L/h/62 kg (IIV 14.8%; IOV 6.6%), which is slightly higher compared with the typical CL of 11.4 L/h/62 kg from the published model by McCune et al. using allometrically scaled NFM on parameters and a maturation component on CL. Using dose-adjustment strategies that assume CL remains the same during the course of treatment (equation from PI using proportional adjustment) could result in a higher-than-expected AUC0–24 following Doses 2–4 and thus a larger AUCcum (Table 4, Figure 2). This can be mitigated by first using a model-based estimation of AUC0–24, which incorporates time-associated CLi estimates (Scenarios MOD_PI_D1 and MOD_PI_D1-4) and, second, by performing sampling after each dose (MOD.PI_D1-4). Simulations comparing the method for estimating AUC0–24 highlight that NCA underestimates AUC0–24, resulting in an adjustment of doses higher than required (comparing Scenarios NCA.PI_D1 and NCA.PI_D1-4 using NCA calculated exposure with Scenarios MOD.PI.D1 and MOD.PI.D1-4 using model-based exposure). The use of daily sampling does not mitigate the impact of using NCA-based AUC0–24 estimates for dose adjustments with 100% of subjects still attaining actual AUCcum estimates above target AUCcum (Figure 2). It has been reported that performing dose adjustments to target a certain exposure increases the risk of toxicities for subjects, and this is likely due to the use of practices in line with Scenarios NCA.PI_D1 and NCA.PI_D1-4 using NCA exposure estimates when the targets in the literature have been estimated using model-based methods. Therefore, it is imperative that the method for exposure estimation is considered when determining the exposure target. The method used to estimate exposure for busulfan and methods used to calculate dose adjustments should be listed and standardized in publications to allow for the correct interpretation of results and implementation into clinical practice.

Scenarios MOD.MOD.D1 and MOD.MOD.D1-4 used the CLi estimated using the final model to guide dose adjustments. When sampling can only be performed following D1, using both model-based AUC0–24 estimation and CLi (Scenario MOD.MOD.D1) resulted in 100% of subjects attaining the target AUCcum ±5% (compared with 0% for Scenarios NCA.PI_D1 and MOD.PI_D1). Whereas when daily sampling and dose adjustment are available, model-based AUC0–24 with dose adjustment using either method.

**FIGURE 2** Boxplot showing cumulative area under the concentration-time curve following all doses (AUCcum) of four once-daily doses of busulfan. Black dot-dash line = target AUCcum of 90 mg · h/L, gray-shaded area = target AUCcum of 90 mg · h/L ±5% (within 85.5–94.5 mg · h/L), gray dashed lines = optimal target range described by Bartelink et al. (within 78–101 mg · h/L). Scenario descriptions can be found in Table 1 and outlying values not shown in the figure. CLi, individual model-based clearance calculated at the end of the dosing interval for the current dose; Model, final model as per article; NCA, noncompartmental analysis; PI (proportional), proportional equation according to product information leaflet.
resulted in 100% of subjects within the target $AUC_{\text{cum}}$ ±5%.

The success of Scenario MOD_MOD_D1 highlights the benefits of using model-based methods for both estimating exposure and calculating next doses. Studies involving reduced sampling scenarios and model-based methods using Bayesian forecasting software have reported adequate precision and accuracy when estimating $AUC_{\text{cum}}$. It is clear that model-based estimation of exposure is important to ensure subjects attain target $AUC_{\text{cum}}$. Use of a population PK model that allows for the reduction of CL during the course of treatment within a Bayesian forecasting software program should be explored in future prospective trials (Scenario MOD_MOD_D1-4; Figure 2).

This study has some limitations. Residual unexplained variability and IOV on both CL and V1, although low (6.6% and 9.7% respectively), were not implemented in the simulations. The data set was collected across four separate hospitals, introducing variable practice in busulfan administration, sample collection, and record keeping. The number of subjects on certain concomitant medications was low, limiting analysis opportunities. The study included retrospective data that relies on the accuracy of documentation.

Time-associated reduction in CL during a typical 4-day course of once-daily i.v. busulfan was described. It is strongly recommended that the antiquated practice of determining busulfan exposure using NCA be retired and replaced by model-based methods using numeric integration, preferably implementing a model that describes a change in CL across the dosing period. Future studies should focus on the use of dose-adjustment strategies, such as that represented in Scenarios MOD_MOD_D1-4 and MOD_PI_D1-4 within Bayesian forecasting software to increase success in achieving individual $AUC_{\text{cum}}$ exposure targets and desired patient outcomes. Sample collection following each dose increases the numbers of patients achieving the cumulative exposure target; however, limited sampling strategies could be useful when model-based methods are implemented for both estimation of exposure and calculating next doses. Lastly, the method used to estimate exposure for outcome analysis and used for dose adjustments in patients should be considered an essential component for reporting in future articles. Standardization of methods for busulfan exposure monitoring and dose adjustment would allow for improved interpretation of results from the literature and implementation into clinical practice.

**AUTHOR CONTRIBUTIONS**

R.L., S.H., C.E.S., C.J.F., S.R., L.T., R.M., and T.O. wrote the manuscript. R.L., S.H., C.E.S., C.J.F., S.R., L.T., R.M., and T.O. designed the research. R.L. performed the research. R.L. and S.H. analyzed the data.

**ACKNOWLEDGMENTS**

The study team thanks the Oncology Department of the Queensland Children’s Hospital (Brisbane, Australia) and all participating Australia and New Zealand Childrens Haematology and Oncology Group (ANZCHOG) centers for their ongoing support in this project. The Australian Centre of Pharmacometrics contributed computing resources and the NONMEM® license required to perform the NLME modeling. Busulfan samples were tested under the direction of Jacobus Ungerer and Brett McWhinney at Pathology Queensland, with thanks. Further acknowledgments are extended to subjects who enrolled in this study and contributed their data. The authors would like to acknowledge the reviewers for their thoughtful and considered feedback which improved the manuscript.

**CONFLICT OF INTEREST**

The authors declared no competing interests for this work. As an Associate Editor for *CPT: Pharmacometrics and Systems Pharmacology*, Stefanie Hennig was not involved in the review or decision process for this article.

**ORCID**

Rachael Lawson © https://orcid.org/0000-0002-0104-5396

Stefanie Hennig © https://orcid.org/0000-0001-5972-3711

**REFERENCES**

1. Bartelink IH, van Kesteren C, Boelens JJ, et al. Predictive performance of a busulfan pharmacokinetic model in children and young adults. *Ther Drug Monit*. 2012;34(5):574-583. doi:10.1097/FTD.0b013e31826051bb

2. Lee JW, Kang HJ, Lee SH, et al. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. *Biol Blood Marrow Transplant*. 2012;18(6):944-950. doi:10.1016/j.bbmt.2011.11.025

3. Long-Boyle JR, Savic R, Yan S, et al. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. *Ther Drug Monit*. 2015;37(2):236-245. doi:10.1097/FTD.0000000000001313

4. McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NH. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. *Clin Cancer Res*. 2014;20(3):754-763. doi:10.1158/1078-0432.Ccr-13-1960

5. Rhee SJ, Lee JW, Yu KS, et al. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram. *Am J Hematol*. 2017;92(7):607-613. doi:10.1002/ajh.24734

6. Gaziev J, Nguyen L, Puozzo C, et al. Novel pharmacokinetic behavior of intravenous busulfan in children with
thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood. 2010;115(22):4597-4604. doi:10.1182/blood-2010-01-265405

7. Kawazoe A, Funaki T, Kim S. Population pharmacokinetic analysis of busulfan in Japanese pediatric and adult HCT patients. J Clin Pharmacol. 2018;58(9):1196-1204. doi:10.1002/jcph.1120

8. El-Serafi I, Terelius Y, Abedi-Valugerdi M, et al. Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway. PLoS One. 2017;12(11):e0187294. doi:10.1371/journal.pone.0187294

9. Younis IR, Elliott M, Peer CJ, et al. Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1. J Pharmacol Exp Ther. 2008;327(3):770-776. doi:10.1124/jpet.108.142208

10. Lawson R, Staatz CE, Fraser CI, Hennig S. Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in Paediatric patients. Clin Pharmacokinet. 2021;60(1):17-51. doi:10.1007/s40262-020-00947-2

11. Langenhorst JB, Boss J, van Kesteren C, et al. A semi-mechanistic model based on glutathione depletion to describe intra-individual reduction in busulfan clearance. Br J Clin Pharmacol. 2020;86(3):1499-1509. doi:10.1111/bcp.14256

12. Otsuka America Pharmaceutical I. Busulfix (busulfan) for Injection. Food and Drug Administration; 2015: ed2015. Accessed June 04, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014bld.pdf

13. Palmer J, McCune JS, Perales MA, et al. Personalizing busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant. 2016;22(11):1915-1925. doi:10.1016/j.bbmt.2016.07.013

14. Andersson BS, Thall PF, Valdez BC, et al. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/ MDS patients. Bone Marrow Transplant. 2017;52(4):580-587. doi:10.1038/bmt.2016.322

15. Bartelink IH, van Reij EML, Gerhardt CE, et al. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow Transplant. 2014;20(3):345-353. doi:10.1016/j.bbmt.2013.11.027

16. Hong KT, Kang HJ, Choi JY, et al. Favorable outcome of post-transplantation cyclophosphamide haploidentical peripheral blood stem cell transplantation with targeted busulfan-based myeloablative conditioning using intensive pharmacokinetic monitoring in pediatric patients. Biol Blood Marrow Transplant. 2018;24(11):2239-2244. doi:10.1016/j.bbmt.2018.06.034

17. Kim B, Lee JW, Hong KT, et al. Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients. Sci Rep. 2017;7(1):1711. doi:10.1038/s41598-017-01861-7

18. Lee JW, Kang HJ, Kim S, et al. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients. Biol Blood Marrow Transplant. 2015;21(1):190-195. doi:10.1016/j.bbmt.2014.09.013

19. Nava T, Kassir N, Rezgui MA, et al. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. Br J Clin Pharmacol. 2018;84(7):1494-1504. doi:10.1111/bcp.13566

20. Bartelink IH, Lalmohamed A, van Reij EM, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016;3(11):e526-e536. doi:10.1016/s2352-3026(16)30114-4

21. Lawson R, Paterson L, Fraser CI, Hennig S. Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation. Cancer Chemother Pharmacol. 2021;88(3):379-391. doi:10.1007/s00280-021-04288-0

22. Feng XY, Wu YJ, Zhang JR, et al. Busulfan systemic exposure and its relationship with efficacy and safety in hematopoietic stem cell transplantation in children: a meta-analysis. BMC Pediatr. 2020;20(1):176. doi:10.1186/s12887-020-02028-6

23. Otsuka Australia. Pharmaceutical Pty.Ltd. Australian Product Information Busulfex (Busulfan). Injection. eMIMs2018. p. 1–21.

24. Chandra S, Chandrakasan S, Saldana BDJ, et al. Experience with a reduced toxicity allogeneic transplant regimen for non-CGD primary immune deficiencies requiring myeloablation. J Clin Immunol. 2021;41(1):89-98. doi:10.1007/s10875-020-00888-2

25. Felber M, Steward CG, Kentouche K, et al. Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis. Blood Adv. 2020;4(9):1998-2010. doi:10.1182/bloodadvances.2020001748

26. Osumi T, Tomizawa D, Kawai T, et al. A prospective study of allogeneic transplantation from unrelated donors for chronic granulomatous disease with target busulfan-based reduced-intensity conditioning. Bone Marrow Transplant. 2019;54(1):168-172. doi:10.1038/s41409-018-0271-9

27. Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokin Pharmacodyn. 2008;35(4):401-421. doi:10.1007/s10875-008-9094-4

28. Poinsignon V, Faivre L, Nguyen L, et al. New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning. Pediatr Blood Cancer. 2020;67:e28603. doi:10.1002/pbc.28603

29. Al-Sallami HS, Goulding A, Grant A, Taylor R, Holford N, Duffull SB. Prediction of fat-free mass in children. Eur J Clin Pharmacol. 2015;54(11):1169-1178. doi:10.1007/s40262-015-0277-z

30. Holford NHG, Anderson BJ. Allometric size: the scientific concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303-332. doi:10.1146/annurev.pharmtox.48.113006.094708
33. ten Brink MH, van Bavel T, Swen JJ, et al. Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation. *Pharmacogenomics*. 2013;14(14):1683-1690. doi:10.2217/pgs.13.159

34. Tse WT, Duerst R, Schneiderman J, Chaudhury S, Jacobsohn D, Kletzel M. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. *Bone Marrow Transplant*. 2009;44(3):145-156. doi:10.1038/bmt.2008.437

35. Browning B, Thormann K, Donaldson A, Halverson T, Shinkle M, Kletzel M. Busulfan dosing in children with BMIs >/= 85% undergoing HSCT: a new optimal strategy. *Biol Blood Marrow Transplant*. 2011;17(9):1383-1388. doi:10.1016/j.bbmt.2011.01.013

36. Ashbee HR, Gilleece MH. Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. *Bone Marrow Transplant*. 2012;47(7):881-894. doi:10.1038/bmt.2011.146

37. DeLeve LD, Wang XD. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. *Pharmacology*. 2000;60(3):143-154. doi:10.1159/000028359

38. Scian M, Atkins WM. The busulfan metabolite EdAG irreversibly glutathionylates glutaredoxins. *Arch Biochem Biophys*. 2015;583:96-104. doi:10.1016/j.abb.2015.08.005

39. Scian M, Atkins WM. Supporting data for characterization of the busulfan metabolite EdAG and the Glutaredoxins that it aducts. *Data Brief*. 2015;5:161-170. doi:10.1016/j.dib.2015.09.002

40. Scian M, Guttman M, Bouldin SD, Outten CE, Atkins WM. The myeloablative drug busulfan converts cysteine to dehydroalanine and lanthionine in Redoxins. *Biochemistry*. 2016;55(33):4720-4730. doi:10.1021/acs.biochem.6b00622

41. Almog S, Kurnik D, Shimoni A, et al. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. *Biol Blood Marrow Transplant*. 2011;17(1):117-123. doi:10.1016/j.bbmt.2010.06.017

42. Bartelink IH, Bredius RG, Ververs TT, et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. *Biol Blood Marrow Transplant*. 2008;14(1):88-98. doi:10.1016/j.bbmt.2007.09.015

43. Strouse C, Zhang Y, Zhang M-J, et al. Risk score for the development of Veno-occlusive disease after allogeneic hematopoietic cell transplant. *Biol Blood Marrow Transplant*. 2018;24:2072-2080. doi:10.1016/j.bbmt.2018.06.013

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Lawson R, Staatz CE, Fraser CJ, et al. Population pharmacokinetic model for once-daily intravenous busulfan in pediatric subjects describing time-associated clearance. *CPT Pharmacometrics Syst Pharmacol*. 2022;11:1002-1017. doi: 10.1002/psp4.12809